J&J is showcasing Caplyta at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Caplyta's MDD adjunctive indication (Nov 2025) is fresh — J&J will be heavily promoting it at APA alongside the established schizophrenia and bipolar labels. The broad psychiatric label (3 major indication areas) makes it directly competitive with AbbVie's Vraylar. Expect head-to-head positioning messages.
Ask about: MDD adjunctive launch uptake (6 months post-approval); how they position Caplyta vs. Vraylar across shared indications; 2026 remission outcomes data; tolerability differentiation (weight, metabolic); bipolar II depression data (Vraylar doesn't have bipolar II). The Caplyta vs. Vraylar rivalry will be a subtext of every psychiatry conversation at APA.
Expanding label across schizophrenia, bipolar, and MDD = ePRO+ captures outcomes across all three with consistent multimodal assessment. VoiceVitals is valuable for schizophrenia speech biomarkers and depression vocal affect tracking. Real-world comparative effectiveness data vs. Vraylar is strategically valuable — Videra can enable head-to-head RWE generation.
Set up a follow-up with J&J's team and Videra Health.
Email Ryan Roberts →